Connect With an Alnylam Educator

Connect with an Alnylam educator

Alnylam Patient Education Liaisons (PELs) are professionals with backgrounds in nursing who can provide education to you and your family about hATTR amyloidosis and answer questions about treatment with AMVUTTRA®, a prescription medicine that treats the polyneuropathy caused by hATTR amyloidosis in adults.

The purpose of the Alnylam Patient Education Liaison (PEL) team is to provide education to patients, their families, and caregivers.

PELs engage with patients one-on-one to provide education, participate in family meetings, and help raise awareness about hATTR amyloidosis in community health organizations
PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team
PELs do not provide medical care or advice
All diagnosis and treatment decisions should be made by you and your doctor

Request to connect with an Alnylam Patient Education Liaison

Request that an Alnylam PEL reach out to you to help answer questions you may have about hATTR amyloidosis or AMVUTTRA. Registration is quick and easy—simply fill out the form below.

*All fields are required unless otherwise noted.

First name*

Last name*

Street address*

City*

State*

Zip code*

Email address

Phone number*

OK to leave voice mail. (Optional)

I would like an Alnylam Patient Education Liaison to contact me with information about hATTR amyloidosis.*

I understand that the Alnylam PEL is not providing me medical advice and is not part of my healthcare team.*

By submitting this form, I agree to the Alnylam Privacy Policy. I am 18 years or older, a US resident, and consent to the processing of my personal data per the terms outlined in the Data Privacy Notification and Consent.*

I understand that Alnylam will use reasonable technical and organizational measures to protect the information I share with the PEL and will not use or disclose it outside of the company.*

I would like to receive updates from Alnylam Pharmaceuticals regarding marketing communications, customer surveys, or for market research surveys. (Optional)

Up next Programs and events

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about AMVUTTRA^® (vutrisiran)?

AMVUTTRA can cause:

Low Vitamin A Levels

Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the arms or legs, pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.

For healthcare providers